脓毒症中右心室流出道多普勒血流分析与经胸超声心动图评估的右心室-肺动脉耦联:一项回顾性探索性研究
本研究为3年期间131例脓毒症ICU患者的回顾性研究,均接受经胸超声心动图联合右心室流出道脉冲波多普勒检查。肺动脉加速时间可测者106例(81%),三尖瓣环收缩期位移/肺动脉收缩压(TAPSE/PASP)可测者77例(73%);73例(69%)肺动脉加速时间≤100 ms;右心室流出道血流切迹15例(14%);右心室-肺动脉解耦联(TAPSE/PASP<0.31 mm/mmHg)15例(19%)。作者结论认为脓毒症中肺血管阻力升高与右心室-肺动脉解耦联见于相当比例患者,无创经胸超声评估可行,这些参数对改善右心室功能障碍定义及治疗和预后价值值得进一步研究。
要点
- 131例脓毒症ICU患者中,肺动脉加速时间可测106例(81%),TAPSE/PASP可测77例(73%),经胸超声心动图无创评估右心室流出道多普勒及右心室-肺动脉耦联可行。
- 73例(69%)肺动脉加速时间≤100 ms,提示肺血管阻力升高在脓毒症中常见。
- 右心室-肺动脉解耦联定义为TAPSE/PASP<0.31 mm/mmHg,见于15例(19%)患者。
- 右心室功能障碍发生率依定义不同而异:主观评估28例(26%)、TAPSE<17 mm 26例(25%)、右心室扩张36例(34%)。
- 右心室扩张加重时右心室-肺动脉耦联比值下降且独立于左心室收缩功能,而TAPSE似乎更易受左心室收缩功能变化影响;作者认为这些参数对改善右心室功能障碍定义及治疗和预后价值值得进一步研究。
适用人群与场景
- 3年期间入住ICU的脓毒症患者131例,均接受经胸超声心动图联合右心室流出道脉冲波多普勒检查。
诊断标准与关键阈值
- 右心室-肺动脉解耦联定义为TAPSE/PASP<0.31 mm/mmHg。
- 肺动脉加速时间≤100 ms提示肺血管阻力升高。
- 右心室功能障碍定义包括主观评估、TAPSE<17 mm和右心室扩张。
研究设计与关键结果
- 本研究为3年期间131例脓毒症ICU患者的回顾性研究,评估经胸超声心动图右心室流出道多普勒血流及右心室-肺动脉耦联。
- 肺动脉加速时间可测106例(81%),TAPSE/PASP可测77例(73%)。
- 73例(69%)肺动脉加速时间≤100 ms,提示肺血管阻力升高常见;右心室流出道血流切迹15例(14%)。
- 在肺动脉加速时间可测的患者中,24例(23%)无法评估三尖瓣反流速度。
- 右心室功能障碍按主观评估、TAPSE<17 mm、右心室扩张定义分别为28例(26%)、26例(25%)、36例(34%);随着右心室功能障碍严重程度增加,肺动脉加速时间呈缩短趋势。
- 右心室-肺动脉解耦联(TAPSE/PASP<0.31 mm/mmHg)见于15例(19%);右心室扩张加重时右心室-肺动脉耦联比值下降且独立于左心室收缩功能,而TAPSE似乎更易受左心室收缩功能变化影响。
证据类型、等级与局限
- 证据类型:回顾性探索性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症中肺血管阻力升高和右心室-肺动脉解耦联见于相当比例患者,经胸超声心动图无创评估可行。
- 作者认为,这些参数在改善右心室功能障碍定义方面的作用及其相对于标准参数的治疗和预后价值值得进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Right ventricular (RV) and pulmonary vascular dysfunction appear to be common in sepsis. RV performance is frequently assessed in isolation, yet its close relationship to afterload means combined analysis with right ventricular outflow tract (RVOT) Doppler and RV-pulmonary arterial (RV-PA) coupling may be more informative than standard assessment techniques. Data on feasibility and utility of these parameters in sepsis are lacking and were explored in this study.
METHODS: This is a retrospective study over a 3-year period of one-hundred and thirty-one patients admitted to ICU with sepsis who underwent transthoracic echocardiography (TTE) with RVOT pulsed wave Doppler. RVOT Doppler flow and RV-PA coupling was evaluated alongside standard measurements of RV systolic function and pulmonary pressures. RVOT Doppler analysis included assessment of pulmonary artery acceleration time (PAAT), velocity time integral and presence of notching. RV-PA coupling was assessed using tricuspid annular planar systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP) ratio.
RESULTS: PAAT was measurable in 106 (81%) patients, and TAPSE/PASP was measurable in 77 (73%). Seventy-three (69%) patients had a PAAT of ≤ 100 ms suggesting raised pulmonary vascular resistance (PVR) is common. RVOT flow notching occurred in 15 (14%) of patients. TRV was unable to be assessed in 24 (23%) patients where measurement of PAAT was possible. RV dysfunction (RVD) was present in 28 (26%), 26 (25%) and 36 (34%) patients if subjective assessment, TAPSE < 17 mm and RV dilatation definitions were used, respectively. There was a trend towards shorter PAAT with increasing severity of RVD. RV-PA uncoupling defined as a TAPSE/PASP < 0.31 mm/mmHg was present in 15 (19%) patients. As RV dilatation increased the RV-PA coupling ratio decreased independent of LV systolic function, whereas TAPSE appeared to be more susceptible to changes in LV systolic function.
CONCLUSION: Raised PVR and RV-PA uncoupling is seen in a significant proportion of patients with sepsis. Non-invasive assessment with TTE is feasible. The role of these parameters in assisting improved definitions of RVD, as well as their therapeutic and prognostic utility against standard parameters, deserves further investigation.
参考来源
- Bowcock EM, Gerhardy B, Huang S, et al. Right ventricular outflow tract Doppler flow analysis and pulmonary arterial coupling by transthoracic echocardiography in sepsis: a retrospective exploratory study. Crit Care. 2022. PMID: 36192793. doi:10.1186/s13054-022-04160-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。